SecBot SecBot
PRESS-RELEASE ·Filed Nov 16, 2026

GTBP

GT Biopharma, Inc.
NEUTRAL
Impact 3/10
Processed19h 55m ago Wirepress-3403335
Press release · Earnings

Price Chart

Loading chart...

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3403335

Track record

12 reports on GTBP

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +41.62% at T+60 after the Aug 14, 2026 report. 6 of 7 went positive at some point.

Filters
  1. Nov 16, 2026today Press Release Neutral 3/10 Viewing Entry $3.72 Now $3.54 −4.97% settles Feb 12
  2. Oct 21, 202627d ago EFFECT Bearish 6/10 Entry $5.41 Now $3.54 +34.66% settles Jan 19
  3. Oct 13, 20264w ago DEF 14A Bearish 7/10 Entry $6.21 Now $3.54 +43.08% settles Jan 11
  4. Oct 9, 20265w ago S-1 Bearish 7/10 Entry $6.80 Now $3.54 +48.01% settles Jan 7
  5. Sep 25, 20267w ago 8-K Neutral 3/10 Entry $6.80 Now $3.54 −48.01% settles Dec 22
  6. Sep 15, 20268w ago 8-K Bearish 7/10 Entry $9.00 Now $3.54 +60.72% settles Dec 9
  7. Sep 3, 202610w ago 8-K Neutral 4/10 Entry $0.2524 Now $3.54 +1300.55% settles Nov 30
  8. Aug 14, 202613w ago Press Release Bearish 5/10 Entry $0.2960 to $0.1728 Now $3.54 −1094.26% ▲ +41.62% +38.58% vs SPY
  9. May 22, 202625w ago 8-K Bearish 7/10 Entry $0.4400 to $0.2754 Now $3.54 −703.41% ▲ +37.41% +40.60% vs SPY
  10. Apr 30, 202628w ago S-1 Bearish 7/10 Entry $0.3430 to $0.3167 Now $3.54 −930.61% ▲ +7.67% +10.74% vs SPY
Showing 10 of 12

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 16, 2026

Fresh GTBP Intelligence

Analysis is for subscribers only.

Subscribe for Full Access